Alzheimer’s ICD 10 research has been increased recently in an attempt to understand the nature of this disease.
Despite the great increase in knowledge, a causal therapy for the disease remains wishful thinking.
Dementias are not only increasing in industrialized nations, but also in China, Africa and India. An estimated 25 million people worldwide suffer from Alzheimer’s dementia – and the growth rates are faster than for breast cancer. The causes of the disease are unclear, although knowledge of molecular processes has increased massively. It is unclear whether and when there will be “the” Alzheimer’s drug at all. Nevertheless, Prof. Dr. medical Harald Hampel (Dublin and Munich) is cautiously optimistic about secondary preventive therapy.
What is Alzheimer’s ICD 10?
Severe setbacks for Alzheimer’s therapy mean three large clinical studies which, despite different “strategies” – according to the different hypotheses on pathophysiology – did not show the hoped-for success, but in some cases serious side effects. 123 clinical studies are currently underway worldwide, the first preventive medical studies are in phases II and III. In July 2008, the pipeline status still included
– 27 substances in phase I
– 25 in phase II and
– 10 in phase III
In the meantime, the number has roughly doubled, according to Prof. Dr. medical Peter Riederer (Würzburg). The strategies remain different, and the substances target a wide variety of systems (glutamatergic, cholinergic, histaminergic, serotonergic, cannabis and inflammatory systems) in addition to the amyloid cascade.
How Does it Work?
The pharmaceutical industry uses different strategies in parallel:
nicotine acetylcholine receptor agonists, acetylcholinesterase inhibitors, gamma and b-secretase, b-amyloid vaccination and protein deposition inhibitors.
The early disruption of glucose metabolism that Prof. Dr. Siegfried Hoyer (Heidelberg) as the long-time chairman of the board of directors of the Brain League is back in focus. Glycogen synthetase kinase 3 inhibitors compete against the changed central glucose utilization with downstream disrupted neuronal insulin transduction; with PPAR* gamma agonists, an approach directly at the insulin receptor is recommended.
On the other hand, the mitochondria could be a central early end of various processes that interact to disrupt the function of these energy powerhouses – ATP delivery and apoptosis, said Prof. Dr. medical Walter Müller (Frankfurt/Main). According to a publication in “The Lancet”, an “ancient” antihistamine from Russia is said to have a mitochondrial target and, according to the published data, spectacular success – contrary to all current hypotheses. According to Müller, however, the substance is currently not available.
Does Surgery Work?
Surgery at a relatively late stage of the disease with advanced neurodegeneration is probably not the ideal starting point for therapy. However, for a study to start in the preclinical phase, instead of the clinical diagnosis,ICD -10 specific and valid biomarkers are developed as parameters. According to Hampel, they seem to have already been found for the amyloid cascade. In neuroimaging, PET is developing in a high-field direction, making even small lesions visible. General practitioner sets the course The prevalence
Alzheimer’s ICD 10 Research is Working
The number of Alzheimer’s patients in old people’s homes is increasing steadily: in 13 Mannheim homes from 55 percent in 1995 to 65 percent in 2003. Of the approximately two million Alzheimer’s patients in need of care, however, only one third is cared for in the home, two thirds are at home provided. According to Dr. Martin Haupt (Düsseldorf) only rarely in the home – and if so, then with tricyclics and conventional neuroleptics. The family doctor is responsible for the diagnosis the most important switchman, and he remains the “hub” in the coordination of the service providers. “But he is not the one who is responsible for everything and not the permanent contact person,” He was committed to communicating the diagnosis to the patient and not trivializing it. The stable phase can be extended through therapy – which gives patients and their relatives the chance to prepare for the difficult times and to discuss further options together.
*PPAR = Peroxisome Proliferator Activated Receptor
Symposium of the Brain League eV “Alzheimer’s Research and Treatment – Outlook and Reality” in Frankfurt am Main
Vision of the Future
With early and comprehensive treatment with drugs and non-drug procedures, the development of Alzheimer’s disease can be slowed down by one to two years. A delay of just five years would reduce the number of Alzheimer’s patients by 50 percent. If it were postponed by ten years, the disease would have all but disappeared.